The U.S. radiopharmaceutical therapies market is projected to grow from USD 1.92 billion in 2025 to approximately USD 6.80 billion by 2034, with a compound annual growth rate (CAGR) of 15.05%. This growth is attributed to the rising prevalence of cancer and the adoption of targeted nuclear medicine. Artificial Intelligence is enhancing diagnostic accuracy and treatment personalization in this field, which is particularly effective for cancers like prostate and thyroid tumors. Strategic partnerships among pharmaceutical companies and research institutions are fostering innovation and expediting product development, while the demand for radiopharmaceuticals is further heightened by an aging population and improved diagnostic imaging capabilities. However, logistical challenges posed by the short half-lives of many radioisotopes and stringent regulatory requirements pose obstacles to broader deployment. Theragnostic applications, which combine diagnosis and therapy into one treatment, are gaining traction, particularly in oncology. The beta therapy segment currently holds the largest market share due to its established use in treating specific cancers, while there is expected growth in targeted alpha therapies as new isotopes are developed. Hospitals remain the predominant end-users of these therapies, benefiting from established infrastructure and expertise in nuclear medicine. With ongoing advancements and increasing R&D investments, the U.S. is positioned as a leader in the commercialization and clinical testing of radiopharmaceuticals.
Fri, 01 Aug 2025 13:46:14 GMT | Precedence Research